The Board and Management of Interlinked Technologies Plc has announced the appointment of Mr Christopher Okoro as its new Managing Director.
Okoro will be replacing Mr Olusegun Layode, who stepped down from the company’s Board following his retirement as announced by the Management.
This was disclosed in a notification sent to the Nigerian Stock Exchange (NSE).
Mr Christopher Okoro’s background: He obtained a Bachelor of Science in Public Administration from Imo State University, an MBA from Lagos State University and an MA in International Business Management from Middlesex University, London.
[READ MORE: Why Google disabled more than 200 YouTube channels]
Okoro is a seasoned banker with over 17 years of professional experience which cuts across Branch Management, Retail and Commercial Banking, Product Development, E-Business and Corporate Strategy. He started his career in 2002 as Operations Officer of Fortune International Bank for 3 years before going on to Access Bank to head their Retail Banking Sector for another two years.
He also served as Branch Manager for Access Bank for three years. After this, he moved to Keystone Bank, retaining his title as Head of Retail sales for an extra four years.
His professional affiliations: Mr Okoro is a member of several local and international professional associations including the Chartered Institute of Bankers of Nigeria (CIBN), Nigeria Institute of Management (Chartered), Institute of Bankers of Nigeria, Nigeria Institute of Management (Chartered), Institute of Credit Administration and the Chartered Institute of Management Accountants. He has a BSc in Public Administration from Imo State University, an MBA from Lagos State University and an MA in International Business Management from Middlesex University, London.
Related development: In another notice sent to the Nigerian Stock Exchange (NSE), the company announced Samuel Agweh & Associates as the new Company Secretary.
The company also announced the appointment of two non-executive directors and the retirement of two other directors from its company.
Mr Chike Ikenga and Mr Surajeen Balarbe Yakubu were announced as the new non-executive directors while Mr Emmanuel Bribena and Mr Balogun Adedayo retired as Directors from the Company’s Board.
The newly appointed Non-Directors and Company Secretary, according to the notice, will provide directions for the Company with their wealth of experience and expertise.
[READ ALSO: Nigeria’s age-long budget cycle conundrum]
Covid-19: WHO approves China’s Sinopharm vaccine
WHO has announced the approval of China’s Sinopharm vaccine for Covid-19 vaccination.
The World Health Organization (WHO) has announced the approval of China’s Sinopharm vaccine for Covid-19 vaccination. The vaccine is reported to have 79% efficacy against covid.
This was disclosed today in a report by Reuters. The vaccine would also be the second Chinese-made vaccine after Sinovac vaccine and would be the first developed outside Europe and North America to receive WHO accreditation.
“This expands the list of COVID-19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine,” WHO Director-General, Tedros Adhanom Ghebreyesus said.
The WHO added that the easy storage requirements make it highly suitable for low-resource settings.
“Its easy storage requirements make it highly suitable for low-resource settings,” a WHO statement said while also disclosing that the vaccine has been approved for people above the age of 18 to receive two shots.
“On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks,” the statement added.
The vaccine was created by Beijing Biological Products Institute, a subsidiary of Sinopharm subsidiary China National Biotec Group, with an efficacy of 79% for all age groups.
The WHO however, admitted that few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group.
In case you missed it
The quest for vaccine efficiency got a major boost earlier this week as Nairametrics reported that the United States government announced that it supports the waiver of Intellectual Property Protections on Covid-19 vaccine development, in a bid to boost the fight against the pandemic, and says it will participate in the Okonjo-Iweala-led WTO negotiation to make it happen.
“Mama Taraba”, Former minister and senator, Aisha Al-Hassan is dead
Ex-Women Affairs minister, Aisha Jummai Al-Hassan, popularly known as Mama Taraba is dead
A former Minister for Women Affairs and ex-Governorship Candidate in Taraba State, Aisha Jummai Al-Hassan, popularly known as Mama Taraba is dead.
According to media reports she died in a hospital on Friday in Cairo, Egypt at the age of 61.
Al-Hassan, who was a former senator of the Federal Republic of Nigeria from Taraba North Senatorial District, was the All Progressive Congress (APC) Governorship Candidate for Taraba in the 2015 general elections.
She later contested for the same seat on the platform of the United Democratic Party in the 2019 general elections after resigning from APC and as a minister in the administration of President Muhammadu Buhari on July 27, 2018.
The former senator was born on the 16th of September, 1959 in Jalingo, Taraba State, to Alhaji Abubakar Ibrahim, Sarkin Ayukan Muri.
Aisha Jummai Al-Hassan attended Muhammed Nya Primary School, Jalingo and LEA Primary School, Tudun Wada, Kaduna before proceeding to Saint Faith College (now GGSS) Kawo Kaduna where she studied between January 1973 and June 1977.
Nairametrics | Company Earnings
Access our Live Feed portal for the latest company earnings as they drop.
- Okomu Oil proposes dividend worth N6.7 billion for shareholders.
- Ardova Plc confirms appointment of Oladeinde Nelson-Cole as secretary.
- Cadbury Nigeria Plc set to hold 56th Annual General Meeting (AGM) on June 16.
- FCMB Group Plc appoints Muibat Ijaiya as Director.
- Afromedia Plc reports a loss after tax of N27.3 million in Q1 2021.